apalutamide
janssen
['apalutamide', 'novo ']
approach: ph 3 two arm trial of 6 mo apalutamide followed by rp or xrt in de novo lv mhspc (target n=566)
accrual start: march 2023
estimated completion: jan 2027 #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧